As of 3:00pm ET
| +0.02 / +1.53%|
Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics, currently being evaluated in ongoing Phase 2b SPIRITUS trial; BTA074, a Phase 2 topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor in Phase 1 development for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment in Phase 2 development for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA.
|Joseph M. Patti||President, CEO & Executive Director|
|Mark P. Colonnese||Chief Financial Officer & Executive Vice President|
|John H. Vernachio||Vice President-Preclinical Development|
|Anna Novotney-Barry||Vice President-Clinical Development|
|Jonas Niaura||Vice President-Corporate Development & Strategy|